---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-012133"
form_type: "8-K"
ticker: null
cik: "0001642375"
company_name: "Guardion Health Sciences, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:43:31.754308+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Guardion Health Sciences FY2023 revenue up 10.8% to $12.2M; selling main asset and planning dissolution

## Summary
- FY2023 revenue $12.2M (+10.8% YoY); net income $0.2M vs $(14.9M) loss prior year; EPS $0.12.
- Viactiv product line generated $11.9M (+11.9% YoY), representing 97.2% of total revenue.
- On Jan 30, 2024, agreed to sell Activ Nutritional (owner of Viactiv) for $17.2M cash, subject to stockholder approval.
- Board proposes voluntary dissolution and liquidation after sale closes; special meeting set for May 23, 2024.

## SEC filing metadata
- accession: 0001493152-24-012133
- form_type: 8-K
- cik: 0001642375
- company_name: Guardion Health Sciences, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642375/000149315224012133/0001493152-24-012133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642375/000149315224012133/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-012133
- JSON: https://secwatch.observer/filing/0001493152-24-012133.json
- Plain text: https://secwatch.observer/filing/0001493152-24-012133.txt

## Key facts
- Earnings Releases
  Guardion Health Sciences, Inc. reported the year ended December 31, 2023 results: revenue $12,248,550, net income $158,033, EPS $0.12.
  - Period: the year ended December 31, 2023
  - Revenue: $12,248,550
  - Net income: $158,033
  - EPS: $0.12
  - Result: reported results
  source text: 31, 2023. The Company also provided a corporate update to stockholders. Financial highlights for the year ended December 31, 2023 include the following: ● Total revenue was $12,248,550 for the year ended December 31, 2023, as compared to $11,049,772 for the year ended December 31, 2022, an increase of $1,198,778, or 10.8%. The Viactiv ® product line generated
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642375/000149315224012133/0001493152-24-012133-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.